David Socks

Chair at Eleusis

David Socks is the Board Chair of Eleusis. In addition to his role at Eleusis, he is the CFO and CBO of Hillevax, as well as a Board Member of Phathom Pharmaceuticals (Nasdaq: PHAT), where he was the founding Chief Executive Officer through the company’s IPO. He previously served as a Venture Partner at Frazier Healthcare Partners, where he helped lead the firm’s company creation efforts, co-founding companies such as Arcutis (Nasdaq: ARQT), Passage Bio (Nasdaq: PASG) and Scout Bio. David has also served as an advisor to Prometheus Bioscience (Nasdaq: RXDX) and PvP Biologics (acquired by Takeda). Previously, he was co-founder, President and COO of Incline Therapeutics (acquired by the Medicines Company) and co-founder and Senior Vice President, Corporate Development and Strategy of Cadence Pharmaceuticals (Nasdaq: CADX; acquired by Mallinckrodt).

David holds a B.S. from Georgetown University and an M.B.A from Stanford University.


  • Chair

    Current role